Neumora Therapeutics Inc.... (NMRA)
1.13
-0.03 (-2.59%)
At close: Mar 21, 2025, 3:59 PM
1.16
2.89%
After-hours: Mar 21, 2025, 07:00 PM EDT
-2.59% (1D)
| Bid | 1.13 |
| Market Cap | 182.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -245.29M |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -1.26 |
| Analyst | Hold |
| Ask | 1.19 |
| Volume | 869,226 |
| Avg. Volume (20D) | 3,324,742 |
| Open | 1.14 |
| Previous Close | 1.16 |
| Day's Range | 1.12 - 1.18 |
| 52-Week Range | 1.12 - 17.19 |
| Beta | 2.60 |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in pa...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2023
Employees 110
Stock Exchange NASDAQ
Ticker Symbol NMRA
Website https://www.neumoratx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for NMRA stock is "Hold." The 12-month stock price forecast is $7, which is an increase of 522.22% from the latest price.
Stock Forecasts2 months ago
+14.29%
Neumora Therapeutics shares are trading higher. B ...
Unlock content with
Pro Subscription
2 months ago
-81.42%
Neumora Therapeutics shares are trading lower after the company announced its Phase 3 KOASTAL study did not demonstrate statistically significant improvement on its primary endpoint.
